

## DURECT Corporation Invites You to Join its Third Quarter 2016 Earnings Conference Call

CUPERTINO, Calif., Oct. 21, 2016 /PRNewswire/ — In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2016 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet onMonday, October 31, 2016 at 4:30 pm Eastern Time (1:30 pm Pacific Time).

A live audio webcast of the presentation will be available by accessing DURECT's homepage at <a href="www.www.durect.com">www.www.durect.com</a> and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

## **About DURECT Corporation**

DURECT is a biopharmaceutical company actively developing new therapeutics based on its Epigenomic Regulator Program and proprietary drug delivery platforms. DUR?928, a new chemical entity in Phase 1 development, is the lead candidate in DURECT's Epigenomic Regulator Program. An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival. Human applications may include acute organ injury and chronic metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). DURECT's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage development program in this category is POSIMIR® (SABER®-Bupivacaine), an investigational analgesic product intended to address key unmet needs in postoperative pain management. Another is REMOXY® ER (oxycodone), an investigational new drug based on DURECT's ORADUR® technology. For more information, please visit www.www.durect.com.

NOTE: POSIMIR<sup>®</sup>, SABER<sup>®</sup>, and ORADUR<sup>®</sup> are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIMIR, REMOXY ER, and DUR-928 are investigational drugs under development and have not been approved for sale by the U.S. Food and Drug Administration or other health authorities.

To view the original version on PR Newswire, visit: <a href="http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-third-quarter-2016-earnings-conference-call-300349340.html">http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-third-quarter-2016-earnings-conference-call-300349340.html</a>

**SOURCE DURECT Corporation** 

Matthew J. Hogan, Chief Financial Officer, 408-777-4936